At present, the aromatase inhibitor Anastrozole, estrogen receptor α inhibitor Fulvestrant and novel nitro fatty acid CXA-10 have all entered the phase 2 clinical study against PAH [48–50]. This evidence concerns the gene CYP19A1 and pulmonary arterial hypertension.